2-(3,4-Dichloro-phenyl)-N-(4-difluoromethoxy-3-methoxy-benzyl)-4-(4-methanesulfonylamino-piperidin-1-yl)-2,N-dimethyl-butyramide | 1131737-41-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(3,4-Dichloro-phenyl)-N-(4-difluoromethoxy-3-methoxy-benzyl)-4-(4-methanesulfonylamino-piperidin-1-yl)-2,N-dimethyl-butyramide
• 英文别名: 2-(3,4-dichlorophenyl)-N-[[4-(difluoromethoxy)-3-methoxyphenyl]methyl]-4-[4-(methanesulfonamido)piperidin-1-yl]-N,2-dimethylbutanamide
• CAS: 1131737-41-1
• 化学式: C₂₇H₃₅Cl₂F₂N₃O₅S
• 分子量: 622.561
• InChiKey: ZALDIWPOIMRXOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  40
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  96.6
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS
  申请人：Knust Henner

  公开号：US20090076081A1

  公开（公告）日：2009-03-19

  The invention relates to a compound of formula wherein Ar 1 , Ar 2 , R 1 , R 2 , R 3 , R 4 , R 5 , and R 5′ or to a pharmaceutically active salt thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

  该发明涉及一种化合物，其化学式为Ar1、Ar2、R1、R2、R3、R4、R5和R5′，或其药用活性盐。这些化合物是用于治疗抑郁症、疼痛、精神病、帕金森病、精神分裂症、焦虑和注意力缺陷多动障碍（ADHD）的高潜力NK-3受体拮抗剂。
• Antiviral 2-Carboxy-Thiophene Compounds
  申请人：Corfield John Andrew

  公开号：US20090136448A1

  公开（公告）日：2009-05-28

  Anti-viral agents of compounds of Formula (I): wherein A, R 1 , R 2 and R 3 are as defined in the specification, processes for their preparation and their use in HCV treatment are provided.

  本发明提供了化合物公式（I）的抗病毒剂，其中A、R1、R2和R3如规范中所定义，以及它们的制备过程和在HCV治疗中的使用。
• PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2200982B1

  公开（公告）日：2012-03-14
• [EN] PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE EN TANT QU'ANTAGONISTES DU RÉCEPTEUR NK3
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009033995A1

  公开（公告）日：2009-03-19

  The invention relates to a compound of general formula (I) wherein Ar1/Ar2 are independently from each other phenyl or pyridinyl, which are optionally substituted by one or two substituents, selected from the group consisting of halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen, lower alkoxy substituted by halogen, lower alkyl substituted by alkoxy, lower alkyl substituted by cyano, lower di-alkyl amino, pyridinyl or cyano; R1 is hydrogen, lower alkyl, -(CH2)2O-lower alkyl, or cycloalkyl: R2 is -S(O)2-lower alkyl or -C(O) -lower alkyl; or R1 and R2 form together with the N-atom to which they are attached a pyrrolidin-2- one or a piperidin-2-one group; R3 is hydrogen, halogen or lower alkyl; R4 is hydrogen or lower alkyl; R5/R5' are independently from each other hydrogen, lower alkyl, lower alkyl substituted by halogen, lower alkyl substituted by hydroxy or cycloalkyl; or R5 and R5' form together with the carbon-atom to which they are attached a cycloalkyl group; or to a pharmaceutically active salt thereof. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).